Amount Raised
$140 Million
Round Type
Post-IPO Equity
Investors
Description
On November 12, 2026, Vir Biotechnology, Inc. entered into an underwriting agreement for the sale of 15 million shares of common stock at $10.00 per share. The offering is expected to close on November 16, 2026, subject to customary conditions. With the option for underwriters to purchase additional shares, total proceeds could reach approximately $161.5 million.
Who else raised in Biotechnology around the same time
Companies in the same sectors as Vir Biotechnology, Inc. that raised within 45 days of this round, from Fundz verified event records.
- Rezolute raised $94M (Post-IPO Equity) on November 16, 2026.
- Raywatt raised $9.9M (Series B) on November 16, 2026.
- Seawolf Therapeutics raised $100M (Seed) on November 16, 2026.
- 201 Therapeutics raised $178K (Seed) on November 16, 2026.
- Boston Medical Sciences raised $35M (Series B) on November 13, 2026.
- Lifeplex Science raised $5.3M (Series A) on November 13, 2026.
Who to call at Vir Biotechnology, Inc., and when
A new round usually means Vir Biotechnology, Inc. is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Vir Biotechnology, Inc. raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Vir Biotechnology, Inc., from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Vir Biotechnology, Inc.. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Vir Biotechnology, Inc. raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Vir Biotechnology, Inc. raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.